Women in Nutraceuticals receives Nutrition Business Journal award
The award for Efforts on Behalf of Industry in 2022 was presented to the nonprofit group whose mission is to advocate for gender parity in the nutraceuticals industry.
Women in Nutraceuticals, the nonprofit industry group advocating for gender parity in the nutraceuticals industry, has received an award from Nutrition Business Journal (NBJ). NBJ’s award for Efforts on Behalf of Industry in 2022 was presented to the nonprofit group whose mission is to advocate for gender parity in the nutraceuticals industry.
The award will be presented on July 26 at an awards dinner at the NBJ Summit event. WIN Board Chair Karen Todd will accept the award for the group.
“Explaining how more women in leadership positions could be a viable boost for the industry’s slowing sales growth was not why Women in Nutraceuticals (WIN) was founded, but the fact that women have insights pivotal to how products are developed and marketed is certainly an attention-grabbing argument for 2022 and 2023,” said Rick Polito, NBJ’s editor-in-chief, in a press release. “Showing how women are essential in leadership, no matter the economic conditions, and then working to put them there made WIN an easy pick for the Efforts on Behalf of Industry Award.”
For information about Women In Nutraceuticals, global WIN events, membership and sponsorship opportunities, volunteer opportunities, and more, visit www.WomenInNutraceuticals.org.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
